000294592 001__ 294592
000294592 005__ 20250530145118.0
000294592 0247_ $$2doi$$a10.1007/s10620-024-08664-7
000294592 0247_ $$2pmid$$apmid:39528850
000294592 0247_ $$2ISSN$$a0002-9211
000294592 0247_ $$2ISSN$$a0163-2116
000294592 0247_ $$2ISSN$$a1573-2568
000294592 0247_ $$2ISSN$$a2168-779X
000294592 037__ $$aDKFZ-2024-02362
000294592 041__ $$aEnglish
000294592 082__ $$a610
000294592 1001_ $$aYoung, Graeme P$$b0
000294592 245__ $$aFecal Immunochemical Test Positivity Thresholds: An International Survey of Population-Based Screening Programs.
000294592 260__ $$aDordrecht$$bSpringer Science + Business Media B.V.$$c2025
000294592 3367_ $$2DRIVER$$aarticle
000294592 3367_ $$2DataCite$$aOutput Types/Journal article
000294592 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748609435_4403$$xReview Article
000294592 3367_ $$2BibTeX$$aARTICLE
000294592 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294592 3367_ $$00$$2EndNote$$aJournal Article
000294592 500__ $$aVolume 70, pages 1637–1645, (2025)
000294592 520__ $$aThe fecal immunochemical test for hemoglobin (FIT) is now a widely used non-invasive test in population-based organized screening programs for colorectal neoplasia. The positivity thresholds of tests currently in use are based on the fecal hemoglobin concentration (f-Hb), but the rationale for the adopted thresholds are not well documented. To understand current global usage of FIT in screening programs we conducted an international survey of the brands of FIT used, the f-Hb positivity threshold applied and the rationale for the choice.All members of the World Endoscopy Organization CRC Screening Committee were invited to complete an eight-element initial electronic survey exploring the key aims. Responses were obtained from 63 individuals, representing 38 specific locations in 28 countries. A follow-up survey on technical issues was offered to the 38 locations, with replies from 17 sites in 13 countries.In-use quantitative FIT were provided by four main manufacturers; Minaris Medical (2 countries), Eiken Chemical Company/Polymedco (21), Alfresa Pharma (2) and Sentinel Diagnostics (4). Of the 38 screening sites, 15 used the threshold of 20 µg hemoglobin/g feces, while thresholds ranged between 8.5 and 120 ug/g in the remainder. Seven explanations were given for adopted FIT thresholds; maximizing the sensitivity for colorectal neoplasia (n = 23) was the most common followed by the availability of colonoscopy resources (n = 18). Predictive value, specificity, and cost effectiveness were less frequently reported as the rationale. Nine sites found it necessary to change the threshold that they had initially selected.This international survey has documented the wide range of FIT positivity thresholds that are in current use. Quantitative FITs enable programs to achieve the desired program outcomes within available resource constraints by adjusting the positivity threshold. This supports the need for enabling positivity threshold adjustment of emerging new screening tests based on novel predictive biomarkers, rather than providing inflexible test endpoints.
000294592 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000294592 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294592 650_7 $$2Other$$aColorectal cancer
000294592 650_7 $$2Other$$aNon-invasive screening tests
000294592 650_7 $$2Other$$aPopulation screening
000294592 650_7 $$2Other$$aPositivity threshold
000294592 650_7 $$2Other$$aQuantitative fecal immunochemical test
000294592 650_7 $$2Other$$aScreening program outcomes
000294592 7001_ $$aBenton, Sally C$$b1
000294592 7001_ $$aBresalier, Robert S$$b2
000294592 7001_ $$aChiu, Han-Mo$$b3
000294592 7001_ $$aDekker, Evelien$$b4
000294592 7001_ $$aFraser, Callum G$$b5
000294592 7001_ $$aFrasa, Marieke A M$$b6
000294592 7001_ $$aHalloran, Stephen P$$b7
000294592 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$udkfz
000294592 7001_ $$aParry, Susan$$b9
000294592 7001_ $$aSelby, Kevin$$b10
000294592 7001_ $$aSenore, Carlo$$b11
000294592 7001_ $$aSingh, Harminder$$b12
000294592 7001_ $$aSymonds, Erin L$$b13
000294592 773__ $$0PERI:(DE-600)2015102-0$$a10.1007/s10620-024-08664-7$$p1637–1645$$tDigestive diseases and sciences$$v70$$x0002-9211$$y2025
000294592 909CO $$ooai:inrepo02.dkfz.de:294592$$pVDB
000294592 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000294592 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000294592 9141_ $$y2024
000294592 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-22$$wger
000294592 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-22$$wger
000294592 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIGEST DIS SCI : 2022$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000294592 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000294592 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000294592 980__ $$ajournal
000294592 980__ $$aVDB
000294592 980__ $$aI:(DE-He78)C070-20160331
000294592 980__ $$aUNRESTRICTED